Abstract: | Onychomycosis is a common disease, accounting for up to 50% of all ungualpathologies. We have been developing a clinical trial (ClinicalTrials.gov:{"type":"clinical-trial","attrs":{"text":"NCT01528813","term_id":"NCT01528813"}}NCT01528813) using a 2940nm Er:YAG laser to fractionally ablate human nails in vivo,aiming to increase topical amorolfine lacquer delivery to the nail unit, increasingthe efficacy of topical treatment of distal and lateral subungual onychomycosis.Partial results have shown an increase in areas of nail plate free of disease. Webelieve that ablative lasers can increase the efficacy of topical onychomycosistreatment. |